Nonalcoholic steatohepatitis (NASH) is projected to be the leading cause of liver transplantation by 2020. Advanced fibrosis (stage F3-F4) on liver biopsy independently predicts all-cause and liver-related mortality in NASH. There are no known efficacious treatments for advanced fibrosis related to NASH. Thiazolidinedione therapy has been extensively evaluated in NASH, and new randomized clinical trials (RCTs) of its efficacy have been completed.
Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis: A Meta-analysis
CASSADER, Maurizio;GAMBINO, Roberto
Last
2017-01-01
Abstract
Nonalcoholic steatohepatitis (NASH) is projected to be the leading cause of liver transplantation by 2020. Advanced fibrosis (stage F3-F4) on liver biopsy independently predicts all-cause and liver-related mortality in NASH. There are no known efficacious treatments for advanced fibrosis related to NASH. Thiazolidinedione therapy has been extensively evaluated in NASH, and new randomized clinical trials (RCTs) of its efficacy have been completed.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis_A Meta-analysis.pdf
Accesso aperto
Tipo di file:
PDF EDITORIALE
Dimensione
479.97 kB
Formato
Adobe PDF
|
479.97 kB | Adobe PDF | Visualizza/Apri |
|
JAMA_2017.pdf
Accesso riservato
Tipo di file:
POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione
726.29 kB
Formato
Adobe PDF
|
726.29 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
